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Abstract
We have previously mapped the interval on Chromosome 4 for a major polycystic kidney
disease modifier (Mpkd) of the B6(Cg)-Cys1cpk/J mouse model of recessive polycystic kidney disease (PKD). Informatic analyses predicted that this interval contains at least three
individual renal cystic disease severity-modulating loci (Mpkd1-3). In the current study, we
provide further validation of these predicted effects using a congenic mouse line carrying
the entire CAST/EiJ (CAST)-derived Mpkd1-3 interval on the C57BL/6J background. We
have also generated a derivative congenic line with a refined CAST-derived Mpkd1-2 interval and demonstrated its dominantly-acting disease-modulating effects (e.g., 4.2-fold
increase in total cyst area; p<0.001). The relative strength of these effects allowed the use
of recombinants from these crosses to fine map the Mpkd2 effects to a <14 Mbp interval
that contains 92 RefSeq sequences. One of them corresponds to the previously described
positional Mpkd2 candidate gene, Kif12. Among the positional Mpkd2 candidates, only
expression of Kif12 correlates strongly with the expression pattern of Cys1 across multiple
anatomical nephron structures and developmental time points. Also, we demonstrate that
Kif12 encodes a primary cilium-associated protein. Together, these data provide genetic
and informatic validation of the predicted renal cystic disease-modulating effects of Mpkd13 loci and implicate Kif12 as the candidate locus for Mpkd2.
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Introduction
The polycystic kidney diseases (PKD) are a major cause of end-stage renal disease [1]. Autosomal dominant PKD (ADPKD; MIM 173900) is caused by mutations in the PKD1 or PKD2
genes [2–5] and autosomal recessive PKD (ARPKD; MIM 263200) results from mutations in
the PKHD1 gene [6, 7].
While ADPKD and ARPKD are considered to be classical Mendelian traits, the disease phenotypes in both forms of PKD are complex with respect to the severity of renal cystic disease
and extrarenal manifestations. Such phenotypic variability is typical even among family members that share identical PKD mutations, suggesting modulating effects of other genetic (i.e.,
co-inherited modifier genes), epigenetic, or environmental factors (summarized by Mrug et al
[8]). Among these modulators of PKD progression, co-inherited modifier gene effects are the
most tractable for experimental investigation. Indeed, previous studies have identified several
quantitative trait locus (QTL) intervals that harbor genetic modifiers of PKD progression.
To date, the most significant QTL that modulates the severity of renal cystic and biliary phenotypes has been mapped to mouse Chromosome (Chr) 4 [9–12]. In previous studies, we have
performed intensive analyses of this interval and discriminated three individual QTL effects on
Chr 4 [8]. These effects were designated as Mpkd1, Mpkd2 and Mpkd3 (MGI:3603220–
3603222). Identification of specific candidate genes underlying the effects of the Mpkd1-3 loci
has been complicated by the extensive span of the Chr 4 QTL complex (~50 cM corresponding
to over 100 Mbp of genomic sequence with ~1000 RefSeq genes). Therefore, we prioritized the
analyses of these positional candidates based on the reported expression in early postnatal kidneys and liver, differential renal expression in kidneys with slowly vs rapidly progressive cystic
kidney disease, and comparative analyses of genomic sequence in selected candidates. These
analyses implicated Kif12 as a strong positional candidate gene for the Mpkd2 effects [8]. All of
these studies were performed in the well-characterized B6(Cg)-Cys1cpk/J (B6-Cys1cpk) mouse
model that phenotypically mimics ARPKD [8, 13–16]. The Cys1-encoded protein cystin is a
primary cilium-associated protein [13].
In the current study, we use congenic strain analyses to fine-map the predicted renal cystic
disease-modulating effects of the Mpkd loci and provide further supportive evidence implicating Kif12 as the candidate Mpkd2 locus based upon genetic, informatic, and immunolocalization analyses.

Results
The congenic CAST/EiJ-derived interval containing the Mpkd1-3 loci
modulates renal cystic disease severity
A congenic line homozygous for the CAST/EiJ (CAST)-derived proximal-medial segment of
Chr 4 on the C57BL/6J (B6) genetic background (B6.CAST.4PM) was developed previously by
mating (B6 × CAST)F1 females with B6 males; the male progeny with the desired microsatellite
marker profile were backcrossed to B6 females; mice at the N6 generation or later were intercrossed. Homozygous lines were selected for propagation [17].
We used a series of microsatellite markers to confirm the CAST origin of the Chr 4 interval
in the B6.CAST.4PM strain, to validate the B6 origin of the other Chromosomes, and to finemap the break point between the proximal CAST and distal B6 intervals on Chr 4, defined by
D4Mit11 and D4Mit204 (57.4–61.2 cM). We then interogressed the Cys1cpk mutation into this
mouse line using a (B6.CAST.4PM x B6-Cys1cpk/+) backcross and established a new line, B6.
CAST.4PM-Cys1cpk/+. We used the same backcross to generate a control Cys1cpk/+ line in
which the entire length of Chr 4 was derived from the B6 strain (B6.4PM-Cys1cpk/+). Since the
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CAST-derived Chr 4 interval in B6.CAST.4PM-Cys1cpk/+ line spans the three Mpkd1, Mpkd2
and Mpkd3 loci (Fig 1a), this congenic line allowed us to more precisely evaluate the CASTderived effects that were identified in our previous studies.
In our initial studies, we characterized the renal cystic disease severity of 10-d old Cys1cpk/cpk
mice generated from the B6.CAST.4PM-Cys1cpk/+cross and compared it to the renal phenotypes of Cys1cpk/cpk mice generated from the B6.4PM-Cys1cpk/+cross. These analyses revealed
strong disease-modulating effects of CAST-derived Mpkd1-3 loci, as evidenced by four indices
of cystic disease severity (Fig 1b). Specifically, kidney length (KL) increased 1.4-fold; total kidney weight (KW), increased 3.3-fold (both p<0.001 by t-test; n = 12 for B6 and n = 7 for
CAST-derived Mpkd1-2 loci); KL adjusted for body length (crown to rump; BL), the KL/BL
ratio, increased 1.6-fold; and KW adjusted for body weight (BW), the KW/BW ratio, increased
by 4.2-fold (both p<0.001). These results are consistent with strong renal cystic disease-modulating effects of the composite Mpkd1-3 locus. Since our experimental design compared the
impact of homozygosity for CAST-derived vs B6-derived Mpkd1-3 loci, the observed differences reflect the sum of various (e.g., dominant, recessive, and additive) disease phenotypemodifying Mpkd1-3 effects.

The CAST-derived Mpkd1-2 locus has a dominantly-acting renal cystic
disease accelerating effect
Our previous studies suggested strong interactions among the individual Mpkd1-3 loci [8]. As
the first step towards determining whether these loci may also act independently, we generated
a new Cys1cpk/+ congenic line, B6.CAST.4PM.P1, in which the CAST-derived Chr 4 interval
included only the proximal segment of Ch 4 that contains Mpkd1 and Mpkd2, but not Mpkd3
(Fig 2a). The breakpoint between the proximal CAST and distal B6 intervals in this new line is
defined by D4Mit80 and D4Mit175 (37.7 cM and 45.7 cM).
To evaluate a subset of dominant renal cystic disease-promoting effects associated with
CAST-derived Mpkd1-2 loci, we generated Cys1cpk/cpk mice heterozygous for the CAST-derived
Mpkd1-2 loci and compared their renal cystic disease severity with Cys1cpk/cpk mice homozygous for B6-derived Mpkd1-2 loci. These two groups were generated in the same B6.
CAST.4PM.P1 x B6-Cys1cpk/+ backcross. Phenotypic analysis at post-natal day 10 revealed
strong disease-accelerating effects of CAST-derived Mpkd1-2 loci, as evidenced by our indices
of cystic disease severity (Fig 2a). Specifically, KL increased by 1.3-fold; KW increased by
2.3-fold (both p<0.001 by t-test; n = 14 for B6- and n = 9- for CAST-derived Mpkd1-2 loci);
the KL/BL ratio increased by 1.2-fold; and the KW/BW ratio increased 1.9-fold (both
p<0.001). These results are consistent with a dominantly-acting, cystic disease-modulating
effect of the CAST-derived Mpkd1-2 loci.
Similar to the weight- and length-derived phenotypes (i.e., KW and KL), renal cystic indices
support the dominantly-acting cystic disease-modulating effects of the CAST-derived Mpkd1-2
locus. The total cyst area increased 4.2-fold, with the cyst area of the medulla increasing
3.9-fold and the cyst area of the cortex increasing 5.6-fold (all p<0.001). However, the CASTderived Mpkd1-2 locus had no effect on total cyst number or number of cysts in either the
medulla or the cortex (Table 1). These data suggest that the Mpkd1-2 loci do not promote renal
cystogenesis per se, but rather modulate renal cystic disease severity.

Fine mapping of the Mpkd2 effects
We adapted a deletion mapping approach [18, 19] to fine map the renal cystic disease-modulating effects of the Mpkd2 locus using 10-d old Cys1cpk/cpk Mpkd1-2 recombinants that were
generated from the B6.CAST.4PM.P1 x B6-Cys1cpk/+ backcross (Fig 3). Using this approach,

PLOS ONE | DOI:10.1371/journal.pone.0135678 August 21, 2015

3 / 15

Mpkd Locus Modulates Renal Cystic Disease Progression

Fig 1. Congenic CAST-derived interval containing the Mpkd1-3 loci and its effects on renal cystic
disease progression. a) The CAST-derived segment of Chr 4 corresponding to Mpkd1-3 interval is
delimited by the distal marker, D4Mit11 (shaded area); the breakpoint between proximal CAST-derived and
distal B6-derived segment of Chr 4 occurred between the markers, D4Mit11 (57.4 cM) and D4Mit204 (61.2
cM). b) The predicted cystic disease-modulating effects of the CAST-derived Mpkd1-3 loci were tested by
comparing surrogates of renal cystic phenotypes (kidney length and weight) in Cys1cpk/cpk mutants
homozygous for the CAST-derived (CAST/Ei; n = 7) vs the B6-derived (B6; n = 12) segment of Chr 4. The
genetic background for both groups was B6. Diamonds represent values for individual animals. The line
indicates the mean value for each group.
doi:10.1371/journal.pone.0135678.g001

we narrowed the Mpkd2 interval to 14 Mbp defined by D4Mit288 and D4Mit83 (Chr 4 position
56,769,379 and 70.962.376). This interval contains 175 gene entries in the NCBI Map Viewer
(http://www.ncbi.nlm.nih.gov; NCBI Mus musculus Annotation Release 104), of which 116 are
RefSeq sequences and 59 sequences correspond to predicted, but as yet uncharacterized genes.
Among the RefSeq sequences, there are 92 protein-encoding genes, 3 microRNAs, and 21
pseudogenes.
We focused our subsequent evaluation of positional Mpkd2 candidates on the subset of the
RefSeq sequences that are expressed in the kidney and liver, the two organs that predominantly express the recessive PKD phenotypes [8]. Based on NCBI Unigene data (http://www.
ncbi.nlm.nih.gov), 33 of these RefSeq sequences are expressed in kidney and liver (Table 2),
and of these, 19 contain a single nucleotide polymorphism (SNP) variant based on comparison of B6 vs CAST genome sequence data (Wellcome Trust Sanger Institute, Mouse Genome
Project Data querying and visualization tool; http://www.sanger.ac.uk). Among these 19
sequences, 11 genes (Ikbkap, Svep1, AI314180, Fkbp15, Hdhd3, Kif12, Col27a1, Akna, Whrn,
Tlr4 and Cdk5rap2) contain at least one amino acid change that in the context of disease
would be predicted to be deleterious using software-based algorithms [20, 21]. In addition,
among the 33 kidney and liver expressed RefSeq sequences mapped to the Mpkd2 interval, 6
genes (Ikbkap, Svep1, Fkbp15, Kif12, Col27a1 and Tlr4) contain an in frame insertion or deletion variant.
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Fig 2. Congenic CAST-derived interval containing the Mpkd1-2 loci and its effects on renal cystic
disease progression. a) The CAST-derived segment of Chr 4 corresponding to Mpkd1-2 interval is
delimited by the marker, D4Mit80 (shaded area). The breakpoint between the proximal CAST/E-derived and
distal B6-derived segment of Chr 4 occurred between markers D4Mit80 (37.7 cM) and D4Mit175 (45.7 cM).
b) The predicted cystic disease-modulating effects of the CAST-derived Mpkd1-2 loci was tested by
comparing the renal cystic phenotypes in Cys1cpk/cpk mutants that were heterozygotes for the CAST-derived
(CAST/Ei; n = 9) Mpkd1-2 interval to Cys1cpk/cpk mutants from the same cross that were homozygous B6 for
the Mpkd1-2 interval (n = 14). The genetic background of both groups was B6. Diamonds represent values
for individual animals. The line indicates the mean value for each group.
doi:10.1371/journal.pone.0135678.g002

Among the Mpkd2-associated genes, Kif12 expression most closely
correlates with the structural and developmental expression pattern of
Cys1
To evaluate the relationships between the renal expression patterns of Cys1 and the genes that
map to the Mpkd2 interval, we compared the transcriptional profiles across 18 different nephron-derived anatomical structures and several development time points using the Genitourinary Molecular Anatomy Project (GUDMAP) Database [http://www.gudmap.org; [22]].
Table 1. Renal cystic indices of mice with one CAST/Ei-derived and one C57BL/6J-derived Mpkd1-2 locus (CAST/Ei.B6) vs. two C57BL/6J-derived
Mpkd1-2 loci (B6.B6)
Mpkd1-2 locus

B6.B6

average
SEM

CAST/
Ei.B6

average
SEM
p-value

Total
Cyst
Number

Total
Tissue
Area
(TA)

Total
Cyst
Area
(CA)

% CA/
TA

Medulla
Cysts
Number

Medulla
Area
(MA)

Medulla
Cyst
Area
(MCA)

%
MCA/
MA

Cortex
Cysts
Number

Cortex
Area
(CoA)

Cortex
Cyst
Area
(CoCA)

%
CoCA/
CoA

554

13.4

1.9

14.2

371

6.9

1.6

23.6

184

6.6

0.3

4.3

14

0.2

0.0

0.2

9

0.1

0.0

0.3

6

0.1

0.0

0.1

532

19.7

7.9

37.1

335

11.8

6.4

50.2

197

7.8

1.6

17.9

11

0.7

8

0.5

6

0.2

0.750

0.002

0.5

1.4

<0.001

<0.001

0.424

0.001

0.4

1.5

<0.001

<0.001

0.659

0.057

0.1

1.2

<0.001

<0.001

all reported areas are in mm2; SEM = standard error of the mean; p-value = signiﬁcance of differences between the B6.B6 and CAST/Ei.B6 averages
doi:10.1371/journal.pone.0135678.t001
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Fig 3. Fine-mapping of renal cystic disease progression-modulating Mpkd2 effects. We adapted a
deletion mapping approach to fine map the dominant cystic disease-modulating effects of the CAST-derived
Mpkd2 locus using genetic recombinants for the Mpkd1-2 interval that were generated from the B6.
CAST.4PM.P1-Cys1cpk/+ x B6-Cys1cpk/+ cross. Specifically, we refined the boundaries of the Mpkd2 interval
with CAST-containing Mpkd1-2 recombinants whose phenotypes (i.e., kidney length) were less than ~2 SD
of the phenotype distribution in the CAST Mpkd1-2 interval homozygotes (black-filled diamonds). The
Mpkd1-2 interval is designated by light shading on upper panel). The refined Mpkd2 interval (dark shaded
area) is delimited by D4Mit288 (28.6 cM, 56.8 Mbp) and D4Mit83 (35.6 cM, 71.0 Mbp). It contains 92 RefSeq
sequences and Kif12 maps to the center of this interval (dashed line). Consistent with the predicted cystic
disease-modulating effects of the Mpkd2 locus, recombinants carrying the refined Mpkd2 interval of CAST
origin had more severe phenotypes (e.g., increased kidney length by 20%; p = 0.004) when compared to
recombinants that did not carry the CAST-derived Mpkd2 interval.
doi:10.1371/journal.pone.0135678.g003

Among the top 100 of the ~40,000 GUDMAP transcript entries that most closely correlate
with the Cys1 expression pattern (S1 Fig), Kif12 ranked fourth in rank correlation (r = 0.819)
and was the only gene that mapped to the Mpkd2 interval. Based on a comparison that used
Cys1 as the query to which all other transcripts in the GUDMAP Database were compared, the
Cys1 expression pattern was also highly correlated with the expression of several key cystogenic
genes (Fig 4), including Pkhd1 (correlation rank 69), the orthologue of principal human
ARPKD gene, and Hnf1b (correlation rank 75), which encodes the transcription factor, hepatocyte nuclear factor-1beta (HNF1B) that directly regulates the expression of several cystogenic
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Table 2. Positional candidates for Mpkd2 effects: a subset expressed in kidney and liver.
Symbol

start

stop

Kidney
[TPM]

Liver
[TPM]

Neonate
[TPM]

Missense
SNP variant

Predicted pathogenicity
of the AA change

Inframe insertion or
deletion variant in CAST
(vs B6)

Ikbkap

56763646

56815131

24

9

46

8

+

single AA del

Ctnnal1

56823807

56878060

56

9

65

1

-

-

Epb4.1l4b

53941976

54093158

8

62

14

3

-

-

Txn1

57956245

57969283

96

45

84

-

-

-

Svep1

58055668

58219468

16

9

74

15

+

single AA ins

AI314180

58812902

58925597

120

45

112

3

+

-

Gng10

59048028

59054771

24

18

65

-

-

-

Ugcg

59189203

59222833

32

8

166

-

-

-

Hsdl2

59594463

59631566

282

36

46

-

-

-

E130308A19Rik

59639199

59767175

8

9

46

-

-

-

Inip

59769642

59783855

48

17

55

-

-

-

Mup4

59969678

59973537

8

7133

-

1

-

-

Mup9

60418046

60421958

24

1849

-

-

-

-

Mup1

60510886

60514832

32

4625

-

-

-

-

Slc31a2

61947479

61959445

32

9

28

1

-

-

Fkbp15

62300342

62360591

48

71

9

3

+

single AA del x1, ins x2

Slc31a1

62021783

62052796

120

162

84

1

-

-

Cdc26

62055623

62069657

32

63

56

-

-

-

Prpf4

62069817

62088024

32

9

28

-

-

-

Hdhd3

62160088

62163234

16

126

9

2

+

-

Alad

62170204

62181097

137

298

93

-

-

-

Pole3

62184832

62186048

24

27

18

-

-

-

Rgs3

62220881

62363369

24

36

121

4

-

-

Ambp

62804313

62815176

8

2018

-

2

-

-

Kif12

62826671

62833165

282

9

280

3

+

ﬁve-AA ins

Col27a1

62876446

62996025

16

27

56

13

+

six-AA del

Akna

63028159

63064388

48

9

46

11

+

-

Whrn

63075944

63156985

8

8

27

2

+

-

Atp6v1g1

63205871

63211735

80

63

18

-

-

-

6330416G13Rik

63221390

63247389

32

9

9

-

-

-

Tlr4

66488845

66503831

16

18

74

9

+

single-AA del

Cdk5rap2

69884058

70071401

40

9

28

12

+

-

Megf9

70092961

70195962

8

36

224

3

-

-

"TPM"—transcripts per million reported at UniGene; "AA"—amino acid
doi:10.1371/journal.pone.0135678.t002

genes including Pkhd1 [summarized by Igarashi et al. [23]], Cys1 [24] and Kif12 [25]. Reciprocal analyses using Kif12 as the query revealed that Kif12 expression is correlated most strongly
with that of the Cys1 gene. Kif12 expression was also highly correlated with the expression of
Pkhd1 (correlation rank 26), and Hnf1b (correlation rank 15).

The Mpkd2 locus-associated gene Kif12 encodes a primary ciliumassociated protein
We have also demonstrated that the Kif12-encoded protein, member 12 (kinesin 12), co-localizes with the primary cilia markers somatostatin receptor 3 [26] and α-tubulin in a principal
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Fig 4. Kif12 expression pattern mimics expression of Cys1. Among ~40,000 transcripts profiled in 18 different renal anatomical structures at different
developmental time-points that were deposited into the GUDMAP Database, Kif12 was the only gene from the Mpkd2 interval whose expression was highly
correlated with that of Cys1. Other non-Chr 4 genes with highly correlated expression patterns included Pkhd1, the mouse orthologue of the gene mutated in
virtually all cases of human ARPKD, and Hnf1b, that encodes a direct transcriptional regulator of Pkhd1, Cys1 and Kif12. In addition, Hnf1b mutations result
in a renal cystic phenotype (MODY5 syndrome; MIM 137920). The heatmap depicts a subset of structures and developmental stages highly relevant to renal
cystic disease. Red shading corresponds to higher expression values; darker shading to lower values.
doi:10.1371/journal.pone.0135678.g004

cell line derived from the mouse internal medullary collecting duct (mIMCD; Fig 5). This
observation provides the first evidence that an Mpkd2 locus-associated gene encodes a primary
cilium-associated protein. Since the protein product of Cys1 localizes to primary cilium
together with most genes involved in renal cystic disease, localization of the Kif12 protein product to primary cilia provides further support for this gene as an Mpkd2 locus candidate.

Discussion
The strong renal cystic disease-modulating effects observed in Cys1cpk/cpk mice carrying the
CAST-derived Mpkd1-3 interval or its Mpkd1-2 derivative, provide further validation of our
initial QTL mapping studies that identified a major effect QTL on Chr 4 [8]. Importantly, the
current study demonstrates that the Mpkd1-3 complex exerts its effects in a fashion that is
independent of previously identified non-Chr 4 QTL [8]. In addition, while our previous studies predicted interactions among genes in the Chr 4 QTL complex [8], the current study shows
that an isolated Mpkd1-2 interval, without the Mpkd3 locus, is sufficient to exert a strong,
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Fig 5. Kinesin 12 localizes to primary apical cilium. Upper panel shows representative immunofluorescent micrographs of kinesin 12 (Kif12; red) colocalized with a GFP-tagged primary cilia marker, somatostatin receptor 3 (Sstr3-GFP; green) in a mIMCD cell line expressing Sstr3-GFP. Lower panel
demonstrates co-localization of kinesin 12 with α-tubulin, another commonly used primary cilia marker. The right upper corner insert represents magnification
of the left uppermost primary apical cilium (highlighted in the lower left panel). Together, these data implicate kinesin 12 as a primary cilia-associated protein.
doi:10.1371/journal.pone.0135678.g005

dominantly-acting effect on renal cystic disease severity. This Mpkd1-2 QTL complex also
modulated the cystic area in the renal cortex and medulla, but did not influence cyst number.
Therefore, we propose that the Mpkd1-2 locus most likely modulates progression of existing
renal cystic disease, rather than initiating new cyst formation, which may be regulated by other
factors known to impact cyst number, such as the renoprotective enzyme, heme oxygenase-1
[16].
We then went on to determine whether the Mpkd2 interval alone contains a gene (or multiple genes) with strong cystic disease-modulating effects. We developed a complementary set of
strategies to assess whether the Mpkd2 effect could result from a coding sequence variant
within a subset of positional gene candidates that are expressed in kidney and liver, the two
organs that predominantly express the recessive PKD phenotypes. This approach identified 11
promising positional Mpkd2 candidates.
While multiple coding variant changes are present within the 11 genes that map to the this
interval (Table 2), only the expression of the previously described candidate, Kif12 [8], is
strongly correlated with the expression of Cys1 across the multiple anatomical nephron
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structures and developmental time points catalogued in the GUDMAP Database. While a complete systematic evaluation of each Mpkd2 positional candidate on protein level is confounded
by limited immunoreagents, we have demonstrated that kinesin 12, the protein encoded by
Kif12, is a primary cilia-associated protein. Together, these data implicate Kif12 as a candidate
genetic modifier within the Mpkd2 interval.
Our interpretation is further supported by the recently described localization of kinesin 12
to polycystin 1 (PC1) positive urinary exosome like vesicles [ELVs; [27]] together with Cys1,
Pkhd1 and Pkd2 encoded proteins. In addition, the expression of Kif12, Pkhd1 and Cys1, are
directly regulated by HNF1β [25]. Since Kif12 expression also strongly correlates with the
expression of HNF1 β, as well as Pkhd1 and Cys1 in the GUDMAP datasets, we propose that
these four genes may define a functional complex that together with Pkd1 [28, 29] modulates
the progression of recessive PKD (Fig 6).
Additional supporting evidence implicating Kif12 as the Mpkd2 modifier gene candidate is
provided by recent studies that demonstrate renal cystic disease-attenuating effects of Kif3a
deletion in Pkd1 and Pkd2 mouse models [30]. Similarities between the N-terminal kinesin
motor domain and the C-terminal cargo-binding domain between kinesin 12 and kinesin 3a
[31] as well as kinesin 17 [32] suggest that kinesin 12 may complement the function of these
motor ciliary proteins. We speculate that the C57BL/6J-associated five amino acid deletion
within the kinesin 12 motor domain may impair function of this protein and have cystic disease-inhibiting effects similar to the Kif3a deletion. Kinesin 12 may also complement the function of other kinesins that direct biogenesis and function of primary cilia, e.g. through
regulation of microtubular dynamics [kinesin 7 [33]] or nucleation of cilia at centrioles [kinesin 24 [34]]. In addition, we note that kinesin 12 is expressed by macrophages [http://www.
ncbi.nlm.nih.gov/geo; e.g., GDS3554 and GDS3555 [35], and GDS2430 [36]] and the C57BL/
6J-associated deletion may alter their function. Macrophages induce proliferation of cystic epithelial cells in the Cys1cpk and Pkd1 models [37, 38] and their markers are abundantly
expressed in kidneys from ARPKD patients [15, 39, 40] as well as Cys1cpk/cpk mice carrying the
CAST-derived Kif12 allele [8, 15, 39].
However, it must be noted that unlike the well-studied anterograde IFT kinesins (e.g., kinesin 3a) that are conserved in most eukaryotic cells, kinesin 12 likely emerged later in evolution
[41], its orthologues appear only in mammals and birds together with orthologues of Pkhd1.
Cys1 so far has only been detected in mammals (based on NCBI Homologene; http://www.
ncbi.nlm.nih.gov). Therefore, while the data presented in this report and supporting evidence
from other recent studies are intriguing, they provide only circumstantial evidence for Kif12 as
the Mpkd2 candidate gene. Further rigorous analyses, such targeted gene conversion experiments, are required to validate Kif12 as the Mpkd2 gene.
While the impact of modifier genes in modulating the ARPKD phenotype is suggested by
intrafamilial variability in disease expression [42–44], this proposition also has yet to be systematically evaluated. Such studies are complicated by compound heterozygosity for the majority of
low frequency PKHD1 mutations. However, a recent study in South African Afrikaners demonstrated a founder effect in which most ARPKD patients are homozygous for a single PKHD1
mutation and yet the clinical phenotypes in this cohort are variable [45]. Such populations provide powerful experimental resources for future studies to test the impact of KIF12 and other
specific candidate modifier genes on disease progression in human ARPKD. In addition, KIF12
variants may modulate the severity of a broader spectrum of hepato-renal fibrocystic disorders
or even trigger a ciliopathy such as KIF7 mutation-induced Joubert syndrome [33].
In summary, we have performed functional validation of the renal cystic disease-modulating
effects associated with the Mpkd1-3 interval. We have demonstrated that the CAST-derived
Mpkd1-2 interval promotes cystic disease progression independently of other loci and in a

PLOS ONE | DOI:10.1371/journal.pone.0135678 August 21, 2015

10 / 15

Mpkd Locus Modulates Renal Cystic Disease Progression

Fig 6. Proposed integration of Kif12 into recessive PKD genetic pathway. Hnf1 β regulates the
transcription of several cystogenic genes including Pkhd1, the mouse orthologue of the principal ARPKD
gene; Cys1, the gene mutated in the cpk model of ARPKD, and Kif12, a candidate modifier of the Cys1cpk/cpk
phenotype. Therefore, we propose that the four proteins encoded by Hnf1b, Cys1, Kif12, and Pkhd1 may
define a functional complex that modulates the progression of recessive PKD (black font). This hypothesis is
supported by the very high correlations among structural and developmental expression patterns of these
four genes (Fig 4). In addition, components of the recessive PKD-associated pathway may interact at
different levels with functional components of ADPKD-associated pathways (white font). For example,
HNF1β also regulates the expression of Pkd2, an ADPKD gene. Furthermore, genetic interaction studies
suggest that abnormal Pkd1 expression sensitizes renal tubular cells to Pkhd1 defects [28, 29]. The latter
interaction may physically occur within the primary apical cilium (shaded oval), where these proteins all colocalize. The proposed Kif12 modulating effect on Cys1 function is designated by dashed line, solid lines
correspond to previously described relationships.
doi:10.1371/journal.pone.0135678.g006

dominantly-acting fashion. We have used Mpkd1-2 recombinants to fine-map the Mpkd2
locus to a 14 Mbp interval with 92 RefSeq sequences and developed convergent lines of experimental evidence that implicate Kif12 as the principal candidate for the Mpkd2 effects. This
work sets the stage for direct hypothesis testing of Kif12 as a genetic modifier using targeted
gene conversion experiments in cpk mice, as well as for initial directed studies of KIF12 as a
genetic modifier in specific human ARPKD populations, such as the Afrikaner cohort.

Materials and Methods
Mice
The C57BL/6J-Cys1cpk/+ mice were obtained from the Jackson Laboratory (Bar Harbor, ME).
The Cys1 mutation arose spontaneously on the B6 background. The congenic line carrying the
CAST-derived proximal to medial segment of chromosome 4 (B6.CAST.4PM) on a B6 background [17]. This CAST fragment corresponds to the Mpkd1-3 interval identified by our previous QTL mapping [8]. We have used non-recombinant F2 mice generated from a (B6.
CAST.4PM x B6-Cys1cpk/+)F1 intercross to establish homozygous B6.CAST.4PM-Cys1cpk/+ and
B6.4PM-Cys1cpk/+ mouse lines. Cystic disease severity in 10-d old Cys1cpk/cpk mice from the B6.
CAST.4PM-Cys1cpk/+ cross was compared to those generated in the B6.4PM-Cys1cpk/+ cross.
Scoring of phenotypes and genotyping with Cys1cpk allele-specific assay has been previously
described [8, 13].
Additional crosses were established to generate the congenic line B6.CAST.4PM.P1, with
the proximal Chr 4 QTL interval that contained the Mpkd1-2 loci. To evaluate the cystic disease-modulating effects of the CAST-derived Mpkd1-2 interval, we backcrossed Cys1cpk/+ F1
mice from the B6.CAST.4PM x B6-Cys1cpk/+ cross to B6-Cys1cpk/+ mice. The resulting Cys1cpk/
cpk
mice were screened for recombinants containing CAST-derived segments spanning the
proximal or distal portion of the Mpkd1-2 interval.
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The integrity of CAST-derived Chr 4 intervals and the remaining B6 genome in these
mouse lines was confirmed using a microsatellite marker-based genome scan [8]. Microsatellite
makers were also used to fine-map the boundaries of CAST-B6 breakpoints on Chr 4.
All protocols were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee. The University of Alabama at Birmingham is fully accredited by
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
International.

Histomorphometry
Paraffin-embedded kidneys were sectioned through the long axis and the hilus and stained
with hematoxylin and eosin. The histomorphometry was performed without knowledge of
experimental classifications using Bioquant Osteo 2013 Version 13.2.60 image analysis software. The data was collected by examining: (i) Total tissue area; (ii) Total cyst area (the area
and number of cysts in the entire kidney was measured using void and outline filters in the
software, the cystic space criteria were set to >4X diameters of the normal proximal tubule
spaces; (iii) Medullary area (we estimated the boundary by using the glomeruli as cortical controls), (iv) Medullary cyst area (by selecting the pixels in the cystic area within the medulla
boundary, we defined the medullary cysts using the same void and outline criteria as above;
these analyses also provided the medulla cyst count); (v) Boundary cysts: to optimize the accuracy of cyst counting, we created an array that allowed us to subtract the cysts from the medulla
if over 50% of the area was within the cortex. All other reported data were calculated as derivatives of the above data. All data were independently validated by an additional reader using a
different microscope and image analysis software according to a previously described protocol
[16].

Cell culture and Immunostaining
The IMCD-K2 cell line derived from SV40 transformed internal medullary collecting duct cells
(mIMCD-K2; [46]) is a well-established renal principal cell line [39]. Cells were plated at confluence and grown in DMEM/F12 medium containing Earle balanced salt solution supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin
(Thermo Fisher Scientific Inc; Waltham, MA), in 5% CO2/95% air at 37°C. Immunostaining
was performed after 3–4 d in culture.
The mIMCD-K2 cell line was stained using standard laboratory protocols. Briefly, the cells
were quickly fixed in -20°C methanol and rehydrated in PBS. We used polyclonal anti-mouse
α-tubulin antibody (Invitrogen Corporation, Carlsbad CA) and polyclonal anti-human kinesin
12 (N-18) antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibodies were
obtained from Invitrogen. Immunostaining was performed after blocking tissue sections for 30
min with PBS containing 1% bovine serum albumin (Sigma). Primary antibody diluted in
blocking buffer was incubated with the tissues for 12-hours at 4°C, followed by four rinses with
PBS. Nuclei were stained with Hoechst No. 33528 (Sigma) diluted 1:1,000 in PBS, rinsed 3
times in PBS, then mounted in Prolong Gold antifade mounting media (Molecular Probes). A
similar approach was applied to immunostaining of a mIMCD cell line stably expressing a
GFP-tagged somatostatin receptor 3; Sstr3-GFP [26]. Stained samples were analyzed using a
fluorescent Leica HC microscope (Leica, Allendale, NJ) and MetaMorph software (Molecular
Devices, Sunnyvale, CA).
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GUDMAP analyses
This study utilized data and analytical tools available from the NIDDK GUDMAP developing
kidney gene expression atlas database (http://www.gudmap.org; April 2011) including the
genome wide gene-expression datasets for developing kidney [22].

Statistical analyses
Statistical evaluations were performed with SPSS 11.5 statistical software package (SPSS Inc.).
Renal cystic phenotypes for both kidneys were combined to give an average phenotypic score
for each mouse. Significance of the differences between the two groups was determined by an
unpaired, two-tailed t-test.

Supporting Information
S1 Fig. Global genome-wide correlation of gene expression patterns to the one of Cys1.
Among ~40,000 transcripts profiled in 18 different renal anatomical structures at different
developmental time-points that were deposited into the GUDMAP Database, the Cys1 expression was highly correlated with the Mpkd2 gene candidate, Kif12.
(PNG)
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